O
LENZ

OrbiMed’s LENZ Therapeutics LENZ Stock Holding History

OrbiMed’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-121,202
Closed -$2.69M – 132
2022
Q3 		$2.69M Hold
121,202
– – 0.05% 118
2022
Q2 		$2.33M Sell
121,202
-102,485
-46% -$2.28M 0.04% 128
2022
Q1 		$7.99M Hold
223,687
– – 0.13% 107
2021
Q4 		$19.5M Buy
223,687
+16,558
+8% +$1.37M 0.25% 87
2021
Q3 		$23.8M Buy
207,129
+49,085
+31% +$7.27M 0.26% 87
2021
Q2 		$34M Buy
+158,044
New +$27.5M 0.34% 74

Other funds holding LENZ

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

OrbiMed's LENZ Position: Q4 2022 in Review

OrbiMed sold out of LENZ Therapeutics (LENZ) in Q4 2022, closing a stake of 121,202 shares — an estimated $2.69M sold.

OrbiMed first reported a position in LENZ in Q2 2021 and held it in 6 quarters. The position peaked at $34M in Q2 2021. 65 funds tracked by Wall St. Rank hold LENZ as of Q4 2022.

  • OrbiMed reported no remaining LENZ Therapeutics position as of Q4 2022 after selling out during the quarter.
  • OrbiMed sold 121,202 LENZ Therapeutics shares in Q4 2022, an estimated $2.69M.
  • OrbiMed first reported a position in LENZ Therapeutics in Q2 2021 and held it in 6 quarters.
  • OrbiMed's LENZ Therapeutics position peaked at $34M in Q2 2021.
  • 65 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2022.

Based on OrbiMed's 13F filing for Q4 2022, filed 14 Feb 2023.